WallStSmart
CRVS

Corvus Pharmaceuticals Inc

NASDAQ: CRVS · HEALTHCARE · BIOTECHNOLOGY

$15.19
+5.34% today

Updated 2026-04-30

Market cap
$1.35B
P/E ratio
P/S ratio
EPS (TTM)
$-0.53
Dividend yield
52W range
$3 – $27
Volume
1.3M

Corvus Pharmaceuticals Inc (CRVS) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item201420152016201720182019202020212022202320242025
Revenue$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Revenue growth (YoY)
Cost of revenue$0.00$148000.00$594000.00$842000.00$847000.00$743000.00$632000.00$460000.00$367000.00$151000.00$85000.00$105000.00
Gross profit$0.00$-148000.00$-594000.00$-842000.00$-847000.00$-743000.00$-632000.00$-460000.00$-367000.00$-151000.00$-85000.00$-105000.00
Gross margin
R&D$41455.00$11.35M$29.36M$46.30M$38.59M$37.98M$31.83M$29.11M$24.47M$16.53M$19.39M$33.72M
SG&A$134182.00$2.42M$7.62M$10.22M$10.64M$10.88M$11.93M$9.52M$8.10M$6.88M$8.16M$9.25M
Operating income$-176000.00$-13.77M$-36.98M$-56.52M$-49.22M$-48.85M$-43.76M$-38.63M$-32.56M$-23.41M$-27.55M$-42.97M
Operating margin
EBITDA$14636.00$-31.19M$-36.38M$-55.68M$-48.38M$-48.11M$-43.13M$-38.17M$-32.20M$-23.26M$-27.46M$-42.97M
EBITDA margin
EBIT$-161000.00$-31.34M$-36.98M$-56.52M$-49.22M$-48.85M$-43.76M$-38.63M$-32.56M$-23.41M$-27.55M$-43.08M
Interest expense$0.00$0.00$601000.00$0.00$2.28M$2.18M$540000.00$15000.00$654000.00$1.58M$1.82M$2.50M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-176000.00$-31.34M$-36.38M$-55.66M$-46.94M$-43.75M$-4.82M$-43.24M$-41.31M$-27.03M$-62.29M$-15.28M
Net income growth (YoY)-17704.0%-16.1%-53.0%+15.7%+6.8%+89.0%-796.6%+4.5%+34.6%-130.5%+75.5%
Profit margin